Related Experiment Video
Updated: May 25, 2026
06:07
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
[Demethylating medication in myelodysplastic syndrome]
Martijn L Manson1, Ellen J B Derissen, Pierre W Wijermans
1Universiteit Utrecht, dept. Farmaceutische Wetenschappen, Utrecht, the Netherlands.
Nederlands Tijdschrift Voor Geneeskunde
|January 27, 2012
Summary
Myelodysplastic syndromes (MDS) are blood disorders often treated with stem cell transplants. Epigenetic drugs like azacitidine and decitabine show promise for MDS treatment with low toxicity in elderly patients.
Area of Science:
- Hematology
- Oncology
- Epigenetics
Background:
- Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
- MDS is characterized by ineffective hematopoiesis, leading to cytopenias and increased risk of transformation to acute myeloid leukemia.
- Allogeneic stem cell transplantation is the only curative option but carries significant risks, especially in elderly patients.
Purpose of the Study:
- To evaluate the efficacy and safety of epigenetic modifying agents in treating myelodysplastic syndromes.
- To explore novel therapeutic strategies for MDS, particularly in elderly populations.
Main Methods:
- Review of studies investigating the use of cytidine analogues, azacitidine and decitabine.
- Analysis of drug mechanisms, focusing on DNA methylation inhibition.
- Assessment of clinical trial data regarding treatment efficacy, toxicity, and tolerability.
Main Results:
- Azacitidine and decitabine demonstrated efficacy in treating patients with myelodysplastic syndromes.
- These epigenetic drugs were found to have low toxicity and were relatively well-tolerated in elderly patients.
- The study highlights the potential of epigenetic manipulation as a therapeutic approach for MDS.
Conclusions:
- Epigenetic modifying agents represent a promising new therapeutic option for myelodysplastic syndromes.
- Low-dose azacitidine and decitabine offer a viable treatment strategy with favorable safety profiles, especially for elderly patients.
- Targeting epigenetic processes provides novel avenues for cancer treatment.
More Related Videos
Related Concept Videos
01:17Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...